The citation for this report is:
Wolowacz SE, Briggs A, Belozeroff V, et al. Estimating health-state utility for economic models in clinical studies: an ISPOR good research practices task force report. Value in Health. 2016; 19(6):704-719.
Decision Modeling for Cost-Utility Analysis
Karen M. Kuntz, ScD, Division of Health Policy and Management, School of Public Health, University of Minnesota, Minneapolis, MN, USA
Response to editorial:
Response to Editorial: Estimating Health-State Utility for Economic Models in Clinical Studies: An ISPOR Good Research Practices Task Force Report
ISPOR Estimating Health-State Utility for Economic Models in Clinical Studies Task Force
Andrew Briggs, DPhil, MSc, Professor of Health Economics, University of Glasgow, Glasgow, UK
Sorrel E. Wolowacz, PhD, Head European Health Economics, RTI Health Solutions, Manchester, UK
Vasily Belozeroff, Health Economics Director, Global Health Economics, Amgen Inc., Thousand Oaks, CA, USA
Philip Clarke, PhD, MEc, Associate Professor of Health Economics, Centre for Health Policy, Programs and Economics, University of Melbourne, Melbourne, Australia
Lynda Doward, MRes, European Head, Patient-Reported Outcomes, RTI Health Solutions, Manchester, UK
Ron Goeree, BA, MA, Director, PATH Research Institute, St. Joseph's Hospital and Professor, Department CE&B, McMaster University, Hamilton, Ontario, Canada
Andrew Lloyd, PhD, DPhil, Director, Bladon Associates Ltd., Oxford, England, UK
Richard Norman, PhD, MSc, BA, Senior Research Fellow, School of Public Health, Curtin University, West Australia, Australia
To develop good practices on utility measurement within the clinical trial program for a new intervention. (1) identify and discuss the issues inherent in the collection of utility data for economic models in clinical studies; (2) provide researchers with an understanding of how to analyze and resolve the issues; (3) develop good practices for the early planning of utility data collection within a product development program and the design of utility data collection during protocol development for a planned clinical trial or study; and (4) develop good practices for analyses and reporting to make best use of the data in economic evaluations.
MEASUREMENT OF HEALTH STATE UTILITY VALUES FOR ECONOMIC MODELS IN CLINICAL STUDIES – FINDINGS OF THE GOOD PRACTICES TASK FORCE
Monday, May 18, 2015 ISPOR 20th International Meeting, Forum Presentation, Philadelphia, PA, USA
HEALTH STATE UTILITY VALUES: MEASURING, MODELLING, AND MAPPING
November 11, 2014 – 17th Annual European Congress, Forum Presentation, Amsterdam, The Netherlands
The task force sent out drafts for review twice during the development process and received verbal comments on work to date during an ISPOR Forum. All comments, many of which were substantive, were read by the task force and addressed as appropriate. The reviewer comments and author responses to the draft report are available upon request to firstname.lastname@example.org.